Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
The Evolving Role of Treatment and Technology in Diabetes Care

The Evolving Role of Treatment and Technology in Diabetes Care

Time-in-Range: A Key Determinant of Quality of Life

Time-in-Range: A Key Determinant of Quality of Life

The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.

The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.

What Are the Signs and Symptoms of ASMD?

What Are the Signs and Symptoms of ASMD?

An Evidence about The Role of Basal Insulin Glargine 300 U/mL Post-GLP-1 Therapy

An Evidence about The Role of Basal Insulin Glargine 300 U/mL Post-GLP-1 Therapy

Connectivity Canvas: Pioneering Diabetes Management with Connected Insulin Caps

Connectivity Canvas: Pioneering Diabetes Management with Connected Insulin Caps

Advancing Therapy with iGlarLixi: Differentiation from other complex regimens

Advancing Therapy with iGlarLixi: Differentiation from other complex regimens

An educational video outlining key data from indirect comparisons of iGlarLixi versus IDegAsp.

Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens

Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens

An educational video outlining key data from indirect comparisons of iGlarLixi versus IDegAsp.

Gaucher

Gaucher

Navigating the Pompe Disease Journey

Navigating the Pompe Disease Journey

Recognizing Key Signs and Symptoms Along the Way

Better care for Fabry

Better care for Fabry

Every Moment Matters on the Fabry Journey

Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options

Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options

Educational video on "Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options" outlining key data from indirect comparisons of iGlarLixi versus IDegAsp.